Masimo Co. (MASI) Holdings Reduced by Martingale Asset Management L P

Martingale Asset Management L P trimmed its position in shares of Masimo Co. (NASDAQ:MASI) by 19.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,011 shares of the medical equipment provider’s stock after selling 11,798 shares during the quarter. Martingale Asset Management L P’s holdings in Masimo were worth $6,229,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MASI. Principal Financial Group Inc. boosted its holdings in Masimo by 2.3% during the first quarter. Principal Financial Group Inc. now owns 209,817 shares of the medical equipment provider’s stock valued at $18,454,000 after purchasing an additional 4,809 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in Masimo during the second quarter valued at approximately $534,000. Xact Kapitalforvaltning AB boosted its holdings in Masimo by 28.0% during the second quarter. Xact Kapitalforvaltning AB now owns 8,230 shares of the medical equipment provider’s stock valued at $804,000 after purchasing an additional 1,800 shares in the last quarter. Bank of Montreal Can boosted its holdings in Masimo by 3.1% during the second quarter. Bank of Montreal Can now owns 44,568 shares of the medical equipment provider’s stock valued at $4,352,000 after purchasing an additional 1,357 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in Masimo by 70.2% during the second quarter. Amalgamated Bank now owns 11,020 shares of the medical equipment provider’s stock valued at $1,076,000 after purchasing an additional 4,545 shares in the last quarter. 88.00% of the stock is owned by institutional investors.

In other news, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $119.45, for a total value of $238,900.00. Following the completion of the transaction, the director now owns 55,832 shares in the company, valued at $6,669,132.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ramshorst David J. Van sold 1,325 shares of Masimo stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $125.00, for a total transaction of $165,625.00. Following the completion of the transaction, the insider now owns 2,325 shares of the company’s stock, valued at approximately $290,625. The disclosure for this sale can be found here. Insiders sold 666,033 shares of company stock valued at $79,900,568 in the last quarter. 12.60% of the stock is currently owned by corporate insiders.

NASDAQ:MASI opened at $102.97 on Friday. Masimo Co. has a 1 year low of $80.69 and a 1 year high of $126.89. The company has a market capitalization of $5.46 billion, a PE ratio of 42.03, a PEG ratio of 2.42 and a beta of 1.11.

Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.02. Masimo had a net margin of 17.08% and a return on equity of 20.29%. The company had revenue of $210.58 million during the quarter, compared to analysts’ expectations of $207.62 million. During the same quarter in the previous year, the company posted $0.56 earnings per share. Masimo’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, sell-side analysts forecast that Masimo Co. will post 2.92 EPS for the current fiscal year.

A number of equities research analysts have weighed in on MASI shares. BidaskClub downgraded Masimo from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. Zacks Investment Research downgraded Masimo from a “buy” rating to a “hold” rating in a report on Friday, November 16th. Stifel Nicolaus lifted their price objective on Masimo from $112.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. Needham & Company LLC started coverage on Masimo in a report on Friday, September 14th. They set a “buy” rating on the stock. Finally, Piper Jaffray Companies lifted their price objective on Masimo to $120.00 and gave the company a “neutral” rating in a report on Thursday, November 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Masimo presently has a consensus rating of “Buy” and a consensus target price of $114.40.

ILLEGAL ACTIVITY WARNING: “Masimo Co. (MASI) Holdings Reduced by Martingale Asset Management L P” was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.wkrb13.com/2018/11/25/masimo-co-masi-holdings-reduced-by-martingale-asset-management-l-p.html.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: What does EPS mean?

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply